Mavyret is an antiviral drug prescribed to treat hepatitis C (HCV). It comes as oral tablets and pellets. Mavyret works by stopping HCV from multiplying, which can cure this condition. Mavyret is ...

Mavyret is a prescription drug for hepatitis C (hep C). Learn about the common, mild, and serious side effects the drug can cause and how to manage them.

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) approved an expanded treatment scope for its drug Mavyret ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

--AbbVie today announced that the U.S. Food and Drug Administration approved a label expansion for MAVYRET ®, an oral pangenotypic direct acting antiviral therapy. HCV is a highly infectious ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes those with acute HCV. This development is significant as it ...

With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

MAVYRET and other medicines may affect each other. This can cause you to have too much or not enough MAVYRET or other medicines in your body.

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir ...